Developing Anesthesia as Post Traumatic Stress Disorder (PTSD) Therapy

Summary

This preclinical phase 1 development study in healthy volunteers seeks to identify if low doses of commonly used non-triggering anesthetic agents might have clinical utility for modulating emotional memory processing and to understand the nature of the brain mechanisms of drug action. Optimally, a drug, dose and brain mechanism of action will be identified that will form the foundation for future use in clinical studies of patients with PTSD.

Conditions

• Healthy

Interventions

DRUG

Dexmedetomidine

A low dose of dexmedetomidine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.

DRUG

Propofol

A low dose of propofol is used during scanning after dose piloting outside the scanner for memory effects and tolerability.

DRUG

Ketamine

A low dose of ketamine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.

DRUG

Nitrous Oxide

A low dose of nitrous oxide is used during scanning after dose piloting outside the scanner for memory effects and tolerability.

DRUG

Placebo

Placebo

Sponsors & Collaborators

• National Institute of Mental Health (NIMH)

  collaborator NIH

• University of California, Irvine

  collaborator OTHER

• Southern California Institute for Research and Education

  lead OTHER

Principal Investigators

• Michael T Alkire, MD · University of California, Irvine and Long Beach VA Medical Center

Study Design

Allocation

NON_RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

35 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2009-09-30

Primary Completion

2017-04-30

Completion

2017-04-30

Countries

• United States

Study Locations